Chin Bin Eap

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


415 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | ...
Sous presse
 
Neurocognition and NMDAR Co-agonists Pathways in Individuals with Treatment Resistant First-Episode Psychosis: a 3-year Follow-up Longitudinal Study
Camporesi S., Xin L., Golay P., Eap C. B., Cleusix M., Cuenod M., Fournier M., Hashimoto K., Jenni R., Ramain J. et al. Molecular Psychiatry. Peer-reviewed.
[serval:BIB_23EAC9CDB4DD]
 
Pharmacokinetics and pharmacodynamics of inhaled nicotine salt and free-base using an e-cigarette: A randomized crossover study.
Christen S.E., Hermann L., Bekka E., Vonwyl C., Hammann F., van der Velpen V., Eap C.B., Benowitz N.L., Haschke M., Liakoni E. Nicotine & tobacco research. Peer-reviewed.
[DOI][Pmid][serval:BIB_93370826C242]
 
Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies.
Ruan C.J., Olmos I., Ricciardi C., Schoretsanitis G., Vincent P.D., Anıl Yağcıoğlu A.E., Eap C.B., Baptista T., Clark S.R., Fernandez-Egea E. et al. Schizophrenia research. Peer-reviewed.
[DOI][Pmid][serval:BIB_6D1104C167D0]
 
Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition.
Schoretsanitis G., Anıl Yağcıoğlu A.E., Ruan C.J., Eap C.B., Molden E., Baptista T., Clark S.R., Fernandez-Egea E., Kim S.H., Lane H.Y. et al. Schizophrenia research. Peer-reviewed.
[DOI][Pmid][serval:BIB_3AF533499666]
2024
 
Associations of Valproate Doses With Weight Gain in Adult Psychiatric Patients: A 1-Year Prospective Cohort Study.
Grosu C., Hatoum W., Piras M., Laaboub N., Ranjbar S., Gamma F., Plessen K.J., von Gunten A., Preisig M., Conus P. et al., 2024/03/27. The Journal of clinical psychiatry, 85 (2). Peer-reviewed.
[DOI][Pmid][serval:BIB_A72057EF44B0]
 
Associations between antipsychotics-induced weight gain and brain networks of impulsivity.
Grosu C., Klauser P., Dwir D., Khadimallah I., Alemán-Gómez Y., Laaboub N., Piras M., Fournier M., Preisig M., Conus P. et al., 2024/03/26. Translational psychiatry, 14 (1) p. 162. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D4DC58764681]
DNA methylation may partly explain psychotropic drug-induced metabolic side effects: results from a prospective 1-month observational study.
Dubath C., Porcu E., Delacrétaz A., Grosu C., Laaboub N., Piras M., von Gunten A., Conus P., Plessen K.J., Kutalik Z. et al., 2024/02/28. Clinical epigenetics, 16 (1) p. 36. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_37368679B832]
 
Metabolic disturbances are risk factors for readmission to psychiatric hospitals in non-smokers but not in smokers: results from a Swiss psychiatric cohort and in first-episode psychosis patients.
Laaboub N., Locatelli I., Grosu C., Piras M., Ngoc T.H., Ranjbar S., Preisig M., Elowe J., von Gunten A., Conus P. et al., 2024. Frontiers in psychiatry, 15 p. 1256416. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5AE0B514404B]
Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study.
De Pieri M., Ferrari M., Pistis G., Gamma F., Marino F., Von Gunten A., Conus P., Cosentino M., Eap C.B., 2024. Frontiers in pharmacology, 15 p. 1274442. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FAEE8634BC1C]
2023
Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis.
Kuzo N., Haen E., Ho D.M., Takeuchi H., Piras M., Eap C.B., de Filippis R., Homan P., Kane J.M., Roy M.A. et al., 2023/10. European archives of psychiatry and clinical neuroscience, 273 (7) pp. 1567-1578. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6547F9D0CF75]
 
Use of pharmacological treatment for posttraumatic stress disorder: Analysis of a psychiatric population in Switzerland and comparison with international guidelines.
Montavon F., Vandenberghe F., Eap C.B., 2023/10. L'Encephale, 49 (5) pp. 446-452. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_29F467041DCE]
 
Prescription d’antipsychotiques chez les adultes : à quoi faut-il être attentif ? [Antipsychotic prescribing in adults : what to watch out for ?]
Grandjean C., Vandenberghe F., Dubath C., Sibailly G., Ansermot N., Crettol Wavre S., Eap C.B., 2023/09/20. Revue medicale suisse, 19 (842) pp. 1707-1712. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A5F7D63D1926]
Is Clozapine-induced Weight Gain Dose-dependent? Results From a Prospective Cohort Study.
Piras M., Chahma J., Ranjbar S., Laaboub N., Grosu C., Plessen K.J., von Gunten A., Conus P., Eap C.B., 2023/07/04. Schizophrenia bulletin, 49 (4) pp. 944-952. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_046228D53864]
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis.
Sjaarda J., Delacrétaz A., Dubath C., Laaboub N., Piras M., Grosu C., Vandenberghe F., Crettol S., Ansermot N., Gamma F. et al., 2023/06. Molecular psychiatry, 28 (6) pp. 2320-2327. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC34831410AA]
The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants.
Garin P., Favre L., Vionnet N., Frantz J., Eap C.B., Vandenberghe F., 2023/05. Obesity surgery, 33 (5) pp. 1422-1430. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EDCDCEA08158]
Evolutions of Metabolic Parameters Following Switches of Psychotropic Drugs: A Longitudinal Cohort Study.
Piras M., Ranjbar S., Laaboub N., Grosu C., Gamma F., Plessen K.J., von Gunten A., Conus P., Eap C.B., 2023/01/03. Schizophrenia bulletin, 49 (1) pp. 24-33. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4FD18F26D483]
Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project.
Monfort A., Cardoso E., Eap C.B., Fischer Fumeaux C.J., Graz M.B., Morisod Harari M., Weisskopf E., Gandia P., Allegaert K., Nordeng H. et al., 2023. Frontiers in psychiatry, 14 p. 1167870. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EE8A9936EA15]
2022
Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium.
Smart S.E., Agbedjro D., Pardiñas A.F., Ajnakina O., Alameda L., Andreassen O.A., Barnes TRE, Berardi D., Camporesi S., Cleusix M. et al., 2022/12. Schizophrenia research, 250 pp. 1-9. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FD83206AB9D6]
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples.
Perry B.I., Vandenberghe F., Garrido-Torres N., Osimo E.F., Piras M., Vazquez-Bourgon J., Upthegrove R., Grosu C., De La Foz V.O., Jones P.B. et al., 2022/11. The Lancet regional health. Europe, 22 p. 100493. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A56B7AE8F057]
CYP2C19 expression modulates affective functioning and hippocampal subiculum volume-a large single-center community-dwelling cohort study.
Grosu C., Trofimova O., Gholam-Rezaee M., Strippoli M.F., Kherif F., Lutti A., Preisig M., Draganski B., Eap C.B., 2022/08/05. Translational psychiatry, 12 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9696FED34BD7]
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.
Laaboub N., Dubath C., Ranjbar S., Sibailly G., Grosu C., Piras M., Délessert D., Richard-Lepouriel H., Ansermot N., Crettol S. et al., 2022/05/17. BMC psychiatry, 22 (1) p. 342. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E9824076089]
Daily Dose Effects of Risperidone on Weight and Other Metabolic Parameters: A Prospective Cohort Study.
Piras M., Dubath C., Gholam M., Laaboub N., Grosu C., Gamma F., Solida A., Plessen K.J., von Gunten A., Conus P. et al., 2022/05/09. The Journal of clinical psychiatry, 83 (4) pp. 21m14110. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F57923246407]
Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.
Schoretsanitis G., Dubath C., Grosu C., Piras M., Laaboub N., Ranjbar S., Ansermot N., Crettol S., Vandenberghe F., Gamma F. et al., 2022/04. Basic & clinical pharmacology & toxicology, 130 (4) pp. 531-541. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_995572119F81]
 
An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.
de Leon J., Schoretsanitis G., Smith R.L., Molden E., Solismaa A., Seppälä N., Kopeček M., Švancer P., Olmos I., Ricciardi C. et al., 2022/03. Pharmacopsychiatry, 55 (2) pp. 73-86. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0D6FBF72C976]
 
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.
de Leon J., Schoretsanitis G., Smith R.L., Molden E., Solismaa A., Seppälä N., Kopeček M., Švancer P., Olmos I., Ricciardi C. et al., 2022/03..
[DOI][WoS][Pmid][serval:BIB_47E634317B4D]
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.
Pardiñas A.F., Smart S.E., Willcocks I.R., Holmans P.A., Dennison C.A., Lynham A.J., Legge S.E., Baune B.T., Bigdeli T.B., Cairns M.J. et al., 2022/03/01. JAMA psychiatry, 79 (3) pp. 260-269. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A9662B16E7C0]
Psychotropic Drug Prescription in Children and Adolescents: Approved Medications in European Countries and the United States.
Smogur M., Onesanu A., Plessen K.J., Eap C.B., Ansermot N., 2022/03. Journal of child and adolescent psychopharmacology, 32 (2) pp. 80-88. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9623F2827944]
Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema.
Buso G., Favre L., Vionnet N., Gonzalez-Rodriguez E., Hans D., Puder J.J., Dubath C., Eap C.B., Raffoul W., Collet T.H. et al., 2022. Obesity facts, 15 (6) pp. 762-773. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0D55E2287696]
Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity.
Guinchat V., Ansermot N., Ing Lorenzini K., Politis D., Daali Y., Eap C.B., Crettol S., 2022. Frontiers in psychiatry, 13 p. 910684. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8AD25DFBCE50]
2021
Gabapentinoïdes : mésusages et addictions [Gabapentinoids : misuses and addictions]
Grandjean C., Crettol Wavre S., Khazaal Y., Sanchis Zozaya J., Ansermot N., Vandenberghe F., Sibailly G., Eap C.B., 2021/12/15. Revue medicale suisse, 17 (763) pp. 2206-2208. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_CADF3E9C3F84]
 
Investigating the Relations Between Caffeine-Derived Metabolites and Plasma Lipids in 2 Population-Based Studies.
Petrovic D., Pruijm M., Ponte B., Dhayat N.A., Ackermann D., Ehret G., Ansermot N., Vogt B., Martin P.Y., Stringhini S. et al., 2021/12. Mayo Clinic proceedings, 96 (12) pp. 3071-3085. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_96BE60BE6909]
Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study.
Dubath C., Piras M., Gholam M., Laaboub N., Grosu C., Sentissi O., Gamma F., Solida A., von Gunten A., Conus P. et al., 2021/11. Pharmacopsychiatry, 54 (6) pp. 279-286. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_615A39552FB8]
Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution.
Lenski M., Sidibé J., Gholam M., Hennart B., Dubath C., Augsburger M., von Gunten A., Conus P., Allorge D., Thomas A. et al., 2021/11. Clinical and translational science, 14 (6) pp. 2544-2555. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B399E4FCFB6A]
Recommandations de prise en charge des mésusages et addictions aux benzodiazepines [Recommendations for management of misuses and addictions to benzodiazepines]
Grandjean C., Crettol Wavre S., Khazaal Y., Sanchis Zozaya J., Ansermot N., Vandenberghe F., Sibailly G., Eap C.B., 2021/10/13. Revue medicale suisse, 17 (754) pp. 1754-1759. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5EEA6C9D3688]
French validation of the M-Back questionnaire: assessing clinicians' knowledge about metabolic syndrome in psychiatry
Golay P., Calderoni M., Eap C. B., Conus P., 2021/10/10. Swiss Archives of Neurology, Psychiatry and Psychotherapy, 105 (w10011). Peer-reviewed.
[URN][DOI][serval:BIB_EE1AACE813FC]
Correction: Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort.
Dubath C., Gholam-Rezaee M., Sjaarda J., Levier A., Saigi-Morgui N., Delacrétaz A., Glatard A., Panczak R., Correll C.U., Solida A. et al., 2021/10/07..
[URN][DOI][WoS][Pmid][serval:BIB_6E304737384E]
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
Eap C.B., Gründer G., Baumann P., Ansermot N., Conca A., Corruble E., Crettol S., Dahl M.L., de Leon J., Greiner C. et al., 2021/10. The world journal of biological psychiatry, 22 (8) pp. 561-628. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6FD14CC75A02]
 
The role of cytochrome P450 enzyme genetic variants in cannabis hyperemesis syndrome-A case report.
Kuzin M., Xepapadakos F., Scharrer I., Augsburger M., Eap C.B., Schoretsanitis G., 2021/07. Basic & clinical pharmacology & toxicology, 129 (1) pp. 82-85. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14FE5ED0F763]
Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population.
Delacrétaz A., Glatard A., Dubath C., Gholam M., Gamma F., von Gunten A., Conus P., Eap C.B., 2021/07. Basic and clinical pharmacology and toxicology, 129 (1) pp. 26-35. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EBB73A5FE75D]
Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort.
Dubath C., Gholam-Rezaee M., Sjaarda J., Levier A., Saigi-Morgui N., Delacrétaz A., Glatard A., Panczak R., Correll C.U., Solida A. et al., 2021/06/26. Translational psychiatry, 11 (1) p. 360. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4391765D562C]
Traitement de l’insomnie, par quoi commencer ? [Treatment of insomnia, with what to start ?]
Grandjean C., Crettol Wavre S., Ansermot N., Vandenberghe F., Sibailly G., Eap C.B., 2021/05/05. Revue medicale suisse, 17 (737) pp. 890-897. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_44F7FFE9FAFC]
Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass.
Vandenberghe F., Gilet P., Daali Y., Favre L., Eap C.B., 2021/03. Obesity surgery, 31 (3) pp. 1353-1356. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_519FDF490519]
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort.
Laaboub N., Gholam M., Sibailly G., Sjaarda J., Delacrétaz A., Dubath C., Grosu C., Piras M., Ansermot N., Crettol S. et al., 2021. Frontiers in psychiatry, 12 p. 756403. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C84BB0F598EF]
2020
Monitoring caffeine intake in children with a questionnaire and urine collection: a cross-sectional study in a convenience sample in Switzerland.
Rios-Leyvraz M., Bochud M., Tabin R., Genin B., Russo M., Rossier M.F., Eap C.B., Bovet P., Chiolero A., 2020/12. European journal of nutrition, 59 (8) pp. 3537-3543. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EFCD3DC46A9A]
Agitation aiguë chez l’adulte : proposition d’un algorithme de traitement psychopharmacologique [Rapid tranquilisation in adults : algorithm proposed for psychopharmacological treatment]
Crettol Wavre S., Ansermot N., Sibailly G., Vandenberghe F., Grandjean C., Teixeira Robalo B., Fassassi Gallo S., Thonney J., Solida-Tozzi A., Conus P. et al., 2020/09/23. Revue medicale suisse, 16 (707) pp. 1751-1755. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7B77DD272619]
 
A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk.
Weisskopf E., Guidi M., Fischer C.J., Bickle Graz M., Beaufils E., Nguyen K.A., Morisod Harari M., Rouiller S., Rothenburger S., Gaucherand P. et al., 2020/08. British journal of clinical pharmacology, 86 (8) pp. 1642-1653. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6EA0D4637119]
The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.
Baumann Pierre, Eap Chin B., Gastpar Markus, 2020/05. Basic & clinical pharmacology & toxicology, 126 (5) pp. 444-447. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D5D86F76E23B]
Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland.
Dubath C., Delacrétaz A., Glatard A., Vollenweider P., Preisig M., Richard-Lepouriel H., Hasler R., Gamma F., Solida A., Thonney J. et al., 2020/03/31. The Journal of clinical psychiatry, 81 (3) pp. 19m12796. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5B06662CFA57]
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.
Glatard A., Guidi M., Delacrétaz A., Dubath C., Grosu C., Laaboub N., von Gunten A., Conus P., Csajka C., Eap C.B., 2020/03. Clinical pharmacokinetics, 59 (3) pp. 371-382. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_750BA5D2C6D5]
A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants.
Kanders S.H., Pisanu C., Bandstein M., Jonsson J., Castelao E., Pistis G., Gholam-Rezaee M., Eap C.B., Preisig M., Schiöth H.B. et al., 2020/02. Drug development research, 81 (1) pp. 102-113. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_81FF9AB1AB58]
 
Pharmacologie du sujet âgé
Eap Chin Bin, Sibailly Guibet, 2020. pp. 155-164 dans Clerc Marie-Thérèse, Mall Jean-Frédéric, von Gunten Armin (eds.) Vademecum de psychiatrie gériatrique chap. 1, RMS éditions, Médecine & Hygiène.
[serval:BIB_C5C3DCD0FAE6]
Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication.
Alameda L., Levier A., Gholam-Rezaee M., Golay P., Vandenberghe F., Delacretaz A., Baumann P., Glatard A., Dubath C., Herane-Vives A. et al., 2020. PloS one, 15 (12) pp. e0242569. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9615E0192FAB]
2019
Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients.
Delacrétaz A., Glatard A., Dubath C., Gholam-Rezaee M., Sanchez-Mut J.V., Gräff J., von Gunten A., Conus P., Eap C.B., 2019/12/26. Clinical epigenetics, 11 (1) p. 198. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7876169F9529]
Caffeine Consumption in Switzerland: Results from the First National Nutrition Survey MenuCH.
Rochat C., Eap C.B., Bochud M., Chatelan A., 2019/12/20. Nutrients, 12 (1). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0BC5D0D7B809]
 
Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.
Schoretsanitis G., de Leon J., Eap C.B., Kane J.M., Paulzen M., 2019/12. CNS drugs, 33 (12) pp. 1201-1222. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5E6C576B9F1C]
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update.
Fischer Fumeaux C.J., Morisod Harari M., Weisskopf E., Eap C.B., Epiney M., Vial Y., Csajka C., Bickle Graz M., Panchaud A., 2019/10. Expert opinion on drug safety, 18 (10) pp. 949-963. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AACEB7EFC408]
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F5C6318349C9]
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
Glatard A., Guidi M., Dobrinas M., Cornuz J., Csajka C., Eap C.B., 2019/07. European journal of clinical pharmacology, 75 (7) pp. 939-949. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1B9CBBB244BC]
Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics: Clinical Determinants of Plasma Lipid Worsening and New-Onset Hypercholesterolemia.
Delacrétaz A., Vandenberghe F., Glatard A., Dubath C., Levier A., Gholam-Rezaee M., Holzer L., Ambresin A.E., Conus P., Eap C.B., 2019/04/09. The Journal of clinical psychiatry, 80 (3). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B98038AE6722]
 
Genetic and clinic predictors of new onset diabetes mellitus after transplantation.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Mueller N.J., Binet I., Van Delden C., Steiger J., Mohacsi P. et al., 2019/02. The pharmacogenomics journal, 19 (1) pp. 53-64. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BA7F0AAB7E2E]
Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients.
Quteineh L., Wójtowicz A., Bochud P.Y., Crettol S., Vandenberghe F., Venetz J.P., Manuel O., Golshayan D., Lehmann R., Mueller N.J. et al., 2019/01. American journal of transplantation, 19 (1) pp. 238-246. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6D920C4CDD77]
Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients.
Ansermot N., Bochatay M., Schläpfer J., Gholam M., Gonthier A., Conus P., Eap C.B., 2019. Therapeutic advances in psychopharmacology, 9 p. 2045125319891386. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_29A9AAC54485]
 
WFSBP guidelines on how to grade treatment evidence for clinical guideline development.
Hasan A., Bandelow B., Yatham L.N., Berk M., Falkai P., Möller H.J., Kasper S., WFSBP Guideline Task Force Chairs, 2019/01. The world journal of biological psychiatry, 20 (1) pp. 2-16. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C747112D377]
2018
Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances
Delacrétaz Aurélie, Vandenberghe Frederik, Glatard Anaïs, Levier Axel, Dubath Céline, Ansermot Nicolas, Crettol Séverine, Gholam-Rezaee Mehdi, Guessous Idris, Bochud Murielle et al., 2018/11/09. Frontiers in Psychiatry, 9.
[URN][DOI][WoS][Pmid][serval:BIB_EFD90D5BB70B]
 
Les antidépresseurs sont-ils efficaces ?
Hengartner Michael P. , Eap Chin Bin , 2018/10/19. Psychoscope 6 p. 34.
[serval:BIB_891BE4AB08A6]
The effect of a single dose of escitalopram on sensorimotor networks.
Weisstanner C., Kägi G., Krammer W., Eap C.B., Wiest R., Missimer J.H., Weder B.J., 2018/06. Brain and behavior, 8 (6) pp. e00975. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E4B45C938200]
 
Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study.
Ponte B., Pruijm M., Ackermann D., Ehret G., Ansermot N., Staessen J.A., Vogt B., Pechère-Bertschi A., Burnier M., Martin P.Y. et al., 2018/05. Mayo Clinic proceedings, 93 (5) pp. 586-596. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9160FD0FD82A]
Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain.
Vandenberghe F., Najar-Giroud A., Holzer L., Conus P., Eap C.B., Ambresin A.E., 2018/05. Journal of child and adolescent psychopharmacology, 28 (4) pp. 258-265. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E2606312F994]
Psychotropic Drug Prescription in Adolescents: A Retrospective Study in a Swiss Psychiatric University Hospital.
Ansermot N., Jordanov V., Smogur M., Holzer L., Eap C.B., 2018/04. Journal of child and adolescent psychopharmacology, 28 (3) pp. 192-204. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_112AFACDE6F0]
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.
Conus P., Seidman L.J., Fournier M., Xin L., Cleusix M., Baumann P.S., Ferrari C., Cousins A., Alameda L., Gholam-Rezaee M. et al., 2018/02/15. Schizophrenia bulletin, 44 (2) pp. 317-327. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8CA869F64DD6]
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia.
Delacrétaz A., Vandenberghe F., Gholam-Rezaee M., Saigi Morgui N., Glatard A., Thonney J., Solida-Tozzi A., Kolly S., Gallo S.F., Baumann P. et al., 2018. Journal of clinical lipidology, 12 (1) pp. 219-229. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B3A7B269E9CC]
2017
Gender-specific alteration of energy balance and circadian locomotor activity in the Crtc1 knockout mouse model of depression.
Rossetti C., Sciarra D., Petit J.M., Eap C.B., Halfon O., Magistretti P.J., Boutrel B., Cardinaux J.R., 2017/12/08. Translational psychiatry, 7 (12) p. 1269. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A52238B6CFF7]
Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs.
Delacrétaz A., Lagares Santos P., Saigi Morgui N., Vandenberghe F., Glatard A., Gholam-Rezaee M., von Gunten A., Conus P., Eap C.B., 2017/12. Pharmacogenetics and genomics, 27 (12) pp. 464-472. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FB1D5A1CCA6F]
Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring
Forni Ogna Valentina, Bassi Isabelle, Menetrey Isabelle, Muller Olivier, Tousset Eric, Fontana Pierre, Eeckhout Eric, Eap Chin B., Vrijens Bernard, Burnier Michel et al., 2017/10/25. Frontiers in Pharmacology, 8 pp. NA. Peer-reviewed.
[URN][DOI][WoS][serval:BIB_6CD4716A9D7A]
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
Glatard A., Dobrinas M., Gholamrezaee M., Lubomirov R., Cornuz J., Csajka C., Eap C.B., 2017/10. Experimental and clinical psychopharmacology, 25 (5) pp. 353-362. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C398035F5631]
Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs.
Delacrétaz A., Zdralovic A., Vandenberghe F., Saigi-Morgui N., Glatard A., Quteineh L., Gholam-Rezaee M., Raffoul W., Applegate L.A., Jafari P. et al., 2017/09/10. Gene, 628 pp. 8-15. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0B119BA2C151]
Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study.
Sikhayeva N., Iskakova A., Saigi-Morgui N., Zholdybaeva E., Eap C.B., Ramanculov E., 2017/07/24. BMC medical genetics, 18 (1) p. 76. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_734834187D90]
 
Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2017/07/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1057 pp. 101-109. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EA86621FAFDC]
 
N-acetyl-cysteine in a double-blind randomized placebo-controlled trial: Towards biomarker guided treatment in early psychosis
Conus P., Fournier M., Xin L., Baumann P., Ferrari C., Cousins A., Alameda L., Golay P., Jenni R., Kashavan M.S. et al., 2017/04. pp. S806 dans European Psychiatry, Elsevier BV.
[DOI][WoS][serval:BIB_64E326AAB999]
 
SA19. N-Acetyl-Cysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
Do Kim, Seidman Larry J., Fournier Margot, Xin Lijing, Cleusix Martine, Baumann Philipp S., Ferrari Carina, Cousins Ann, Alameda Luis, Gholam-Rezaee Mehdi et al., 2017/03/01. pp. S119-S120 dans Schizophrenia Bulletin, Oxford University Press (OUP).
[DOI][serval:BIB_B2948ECEE2C3]
 
Étude rétrospective sur le suivi électrocardiographique (ECG) des patients hospitalisés en psychiatrie adulte
Ansermot N., Bochatay M., Schläpfer J., Gholamrezaee M., Gonthier A., Conus P., Eap C., 2017/03., 20e journées franco-suisses de pharmacie hospitalière pp. e15-e16 dans Le Pharmacien Hospitalier et Clinicien, Elsevier BV.
[DOI][serval:BIB_B97F5A878EBF]
 
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts
Saigi-Morgui Nuria, Vandenberghe Frederik, Delacrétaz Aurélie, Quteineh Lina, Gholamrezaee Mehdi, Kutalik Zoltan, Aubry Jean Michel, von Gunten Armin, Conus Philippe, Eap Chin B., 2017., 23rd Annual world congress of Psychiatric Genetics (WCPG), Toronto, Canada pp. S248 dans European Neuropsychopharmacology, Elsevier BV.
[DOI][serval:BIB_F48AF55AFB3A]
CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation.
Quteineh L., Bochud P.Y., Golshayan D., Crettol S., Venetz J.P., Manuel O., Kutalik Z., Treyer A., Lehmann R., Mueller N.J. et al., 2017/01. The pharmacogenomics journal, 17 (1) pp. 69-75. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_342B86B6E988]
2016
 
Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior.
Cornelis M.C., Kacprowski T., Menni C., Gustafsson S., Pivin E., Adamski J., Artati A., Eap C.B., Ehret G., Friedrich N. et al., 2016/12/15. Human molecular genetics, 25 (24) pp. 5472-5482. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AC25015ABE94]
 
Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study.
Forni Ogna V., Menetrey I., Muller O., Tousset E., Guihard L., Fontana P., Eeckhout E., Eap C.B., Vrijens B., Burnier M. et al., 2016/12. British Journal of Clinical Pharmacology, 82 (6) pp. 1486-1497. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75F62C85EC0C]
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C., Crettol S., Guidi M., Eap C.B., 2016/12. Clinical pharmacokinetics, 55 (12) pp. 1521-1533. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_038FD2A79BD0]
Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.
Vandenberghe F., Saigí-Morgui N., Delacrétaz A., Quteineh L., Crettol S., Ansermot N., Gholam-Rezaee M., von Gunten A., Conus P., Eap C.B., 2016/12. Pharmacogenetics and genomics, 26 (12) pp. 547-557. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BFD29890FF60]
 
Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2016/11/30. Journal of pharmaceutical and biomedical analysis, 131 pp. 233-245. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B83BFE02B0D1]
Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.
Eap C.B., 2016/09. Dialogues in clinical neuroscience, 18 (3) pp. 313-322. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_63D1914A4F1D]
Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.
Quteineh L., Preisig M., Rivera M., Milaneschi Y., Castelao E., Gholam-Rezaee M., Vandenberghe F., Saigi-Morgui N., Delacrétaz A., Cardinaux J.R. et al., 2016/07/01. Journal of affective disorders, 198 pp. 43-49. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB055B9E66F0]
 
Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts.
Marie-Claire C., Crettol S., Cagnard N., Bloch V., Mouly S., Laplanche J.L., Bellivier F., Lepine J.P., Eap C., Vorspan F., 2016/02. Epigenomics, 8 (2) pp. 181-195. Peer-reviewed.
[DOI][Pmid][serval:BIB_8A903190C0C4]
 
Psychiatrie [New developments in psychiatry]
Conus P., Herrera F., Berney S., Gailland B., Beretta V., Vandenberghe F., Eap C.B., 2016/01/13. Revue medicale suisse, 12 (500) pp. 86-89. Peer-reviewed.
[Pmid][serval:BIB_6F65192527D5]
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts.
Saigi-Morgui N., Vandenberghe F., Delacrétaz A., Quteineh L., Gholamrezaee M., Aubry J.M., von Gunten A., Kutalik Z., Conus P., Eap C.B., 2016. Pharmacogenetics and Genomics, 26 (5) pp. 208-217. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3012FE323A7B]
 
Bon usage des antidépresseurs ISRS durant la grossesse--le défi de l'évaluation de la balance bénéfice-risque [SSRI antidepressant use during pregnancy and the assessment of the risk-benefit ratio].
Weisskopf E., Fumeaux C.J., Bickle Graz M., Harari M.M., Epiney M., Tolsa C.B., Rouiller S., Tolsa J.F., Eap C.B., Vial Y. et al., 2016. Revue Médicale Suisse, 12 (510) pp. 561-566. Peer-reviewed.
[Pmid][serval:BIB_C18A424B9682]
Eine unerwünschte Wirkung von Methadon und Moxifloxacin
Liakoni E., Huber X., Stegert M., Crettol S., Eap CB., Liechti ME., 2016. Schweizerisches Medizin-Forum, 16 pp. 176-177. Peer-reviewed.
[URN][serval:BIB_21191F2448D1]
Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone.
Paulzen M., Eap C.B., Gründer G., Kuzin M., 2016. Journal of Clinical Psychopharmacology, 36 (1) pp. 90-92. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC9F570285D8]
Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population.
Petrovic D., Estoppey Younes S., Pruijm M., Ponte B., Ackermann D., Ehret G., Ansermot N., Mohaupt M., Paccaud F., Vogt B. et al., 2016. Nutrition & metabolism, 13 p. 81. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F638EC8299DC]
Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations.
Saigi-Morgui N., Quteineh L., Bochud P.Y., Crettol S., Kutalik Z., Wojtowicz A., Bibert S., Beckmann S., Mueller N.J., Binet I. et al., 2016. PloS one, 11 (10) pp. e0164443. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ADE82491851D]
Wolff-Parkinson-White syndrome in an adolescent with depression
Chen Fei, Richard Sandra, D'Andrea Géraldine, Grandjean Christophe, Eap Chin B., 2016. Swiss Archives of Neurology Psychiatry and Psychotherapy, 167 (3) pp. 94-96. Peer-reviewed.
[URN][serval:BIB_0CD07346FEF8]
2015
 
1C.06: Ambulatory pulse pressure is negatively associated with excretions of urinary caffeine and its metabolites
Guessous I., Pruijm M., Ponte B., Ehret G., Ansermot N., Vuistiner P., Staessen J.A., Gu Y.M., Paccaud F., Mohaupt M.G. et al., 2015/06., ESH 2015: 25th European meeting on hypertension and cardiovascular protection, 12-15 June 2015, Milan (Italy) pp. e10-e11 dans J Hypertension. Peer-reviewed.
[DOI][Pmid][serval:BIB_408916E57FC5]
 
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients with psychotropic treatments
Quteineh L., Vandenberghe F., Saigi Morgui N., Delacretaz A., Choong E., Gholam-Rezaee M., Magistretti P., Bondolfi G., von Gunten A., Preisig M. et al., 2015/06. dans 12th World Congress of Biological Psychiatry, Athens, Greece, June 14-18, 2015.
[serval:BIB_3618F8958220]
 
Influence of MCHR2 and MCHR2-AS1 genetic polymorphisms on body mass index in psychiatric patients and in subjects from the general population with present or past atypical depression
Choong E., Delacretaz A., Preisig M., Vandenberghe F., Saigi Morgui N., Quteineh L., Gholam-Rezaee M., Kutalik Z., Castelao P., Aubry J.-M. et al., 2015/06. dans 12th World congress of Biological Psychiatry (WFSBP)- 14 – 18 june 2015 - Athens, Greece.
[serval:BIB_1BAEC4811834]
 
Severe manic episode associated with tramadol in a patient with recurrent depressive disorder.
Ansermot N., Chocron O., Herrera F., Eap C.B., 2015/04. Journal of clinical psychopharmacology, 35 (2) pp. 203-204. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_396C716C67CD]
 
Adolescent psychotropic drug use in a Swiss psychiatric university hospital: retrospective studies in 2008 and 2014
Jordanov V., Smogur M., Holzer L., Eap C., Ansermot N., 2015. dans GSASA-Kongress 2015.
[serval:BIB_78ADB907CD2E]
Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments.
Saigi-Morgui N., Vandenberghe F., Delacrétaz A., Quteineh L., Choong E., Gholamrezaee M., Magistretti P., Aubry J.M., von Gunten A., Preisig M. et al., 2015. Journal of Clinical Psychopharmacology, 35 (5) pp. 544-552. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_65A415095D9E]
 
Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions.
Guessous I., Pruijm M., Ponte B., Ackermann D., Ehret G., Ansermot N., Vuistiner P., Staessen J., Gu Y., Paccaud F. et al., 2015. Hypertension, 65 (3) pp. 691-696. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C5A6ADCBDFAD]
 
Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.
Liu Y., Jann M., Vandenberg C., Eap C.B., Shamsi S.A., 2015. Journal of Chromatography. A, 1420 pp. 119-128. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C79E913C6C8]
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F., Guidi M., Choong E., von Gunten A., Conus P., Csajka C., Eap C.B., 2015. Clinical Pharmacokinetics, 54 (12) pp. 1259-1272. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_594496D78157]
Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments.
Quteineh L., Vandenberghe F., Saigi Morgui N., Delacrétaz A., Choong E., Gholam-Rezaee M., Magistretti P., Bondolfi G., Von Gunten A., Preisig M. et al., 2015. Pharmacogenetics and Genomics, 25 (5) pp. 246-258. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_361B0D4F6D36]
Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.
Vandenberghe F., Gholam-Rezaee M., Saigí-Morgui N., Delacrétaz A., Choong E., Solida-Tozzi A., Kolly S., Thonney J., Gallo S.F., Hedjal A. et al., 2015. Journal of Clinical Psychiatry, 76 (11) pp. e1417-e1423. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3DE3D0341247]
Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression.
Delacrétaz A., Preisig M., Vandenberghe F., Saigi Morgui N., Quteineh L., Choong E., Gholam-Rezaee M., Kutalik Z., Magistretti P., Aubry J.M. et al., 2015. Plos One, 10 (10) pp. e0139155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_200412067B84]
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.
Weisskopf E., Fischer C.J., Bickle Graz M., Morisod Harari M., Tolsa J.F., Claris O., Vial Y., Eap C.B., Csajka C., Panchaud A., 2015. Expert Opinion On Drug Safety, 14 (3) pp. 413-427. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A6E08AD4EF04]
 
The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens.
Sakae D.Y., Marti F., Lecca S., Vorspan F., Martín-García E., Morel L.J., Henrion A., Gutiérrez-Cuesta J., Besnard A., Heck N. et al., 2015. Molecular Psychiatry, 20 (11) pp. 1448-1459. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A7353BF80F5C]
2014
 
Blood pressure in relation to coffee and caffeine consumption.
Guessous I., Eap C.B., Bochud M., 2014. Current Hypertension Reports, 16 (9) p. 468. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_489B1F7302C4]
Can Valproic Acid be an Inducer of Clozapine Metabolism?
Diaz F.J., Eap C.B., Ansermot N., Crettol S., Spina E., de Leon J., 2014. Pharmacopsychiatry, 47 (3) pp. 89-96. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B56EBAE8B792]
 
CRTC3 Polymorphisms are not associated with obesity in swiss psychiatric populations
Quteineh L, Vandenberghe F, Rezaee MG, Choong E, Morgui NS, Delacretaz A, Preisig M, Von Gunten A, Conus P, Eap C., 2014. dans European Psychiatry. Peer-reviewed.
[DOI][serval:BIB_21280335216B]
 
CRTC3 POLYMORPHISMS ARE NOT ASSOCIATED WITH OBESITY IN SWISS PSYCHIATRIC POPULATIONS
Quteineh L., Vandenberghe F., Rezaee M. G., Choong E., Morgui N. S., Delacretaz A., Preisig M., Von Gunten A., Conus P., Eap C., 2014., chuv.
[WoS][serval:BIB_11D721FCFAEB]
 
Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique [Pharmacokinetic Alterations in Pregnancy and Use of Therapeutic Drug Monitoring].
Panchaud A., Weisskopf E., Winterfeld U., Baud D., Guidi M., Eap C.B., Csajka C., Widmer N., 2014. Therapie, 69 (3) pp. 223-234. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18592A49D874]
 
Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.
Crettol S., de Leon J., Hiemke C., Eap C.B., 2014. Clinical Pharmacology and Therapeutics, 95 (3) pp. 254-257. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_279EB3D167CB]
 
Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt.
Paulzen M., Henkel K., Tauber S., Reich A., Eap C.B., Gründer G., 2014. Journal of Clinical Psychopharmacology, 34 (3) pp. 398-399. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D82D30EF7FDB]
 
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Stancu I., Alnawaqil A.M., Bula C. et al., 2014. British Journal of Clinical Pharmacology, 78 (1) pp. 135-144. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D0309E8CA034]
 
Predictive values of apetite and early weight increase for long-term weight variation during psychotropic treatment
Vandenberghe F, Rezaee MG, Choong E, Morgui NS, Delacretaz A, Preisig M, Von Gunten A, Conus P, Eap C., 2014. dans European Psychiatry. Peer-reviewed.
[DOI][WoS][serval:BIB_2A8C03791C10]
 
Prescription de médicaments psychotropes chez des adolescents hospitalisés en milieu psychiatrique
Ansermot N, Smogur M, Holzer L, Eap Chin B, 2014. dans 2ème congrès suisse des pharmaciens.
[serval:BIB_EA57A5110A2A]
 
Quantification of typical antipsychotics in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring.
Gradinaru J., Vullioud A., Eap C.B., Ansermot N., 2014. Journal of Pharmaceutical and Biomedical Analysis, 88 pp. 36-44. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5D0365228365]
 
Serotonin toxicity after addition of mirtazapine to escitalopram.
Ansermot N., Hodel P.F., Eap C.B., 2014. Journal of Clinical Psychopharmacology, 34 (4) pp. 540-541. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E75CEBD3530]
2013
 
Population pharmacokinetic study of memantine: effects of clinical and genetic factors.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Alnawaqil A.M., Maurer S., Zumbach S. et al., 2013/03. Clinical pharmacokinetics, 52 (3) pp. 211-223. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6598521C6000]
 
Antidépresseurs, grossesse et allaitement : une étude multicentrique
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J-F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
[serval:BIB_73EE20F9060C]
 
Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry.
Lüthi G., Blangy V., Eap C.B., Ansermot N., 2013. Journal of Pharmaceutical and Biomedical Analysis, 77 pp. 1-8. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F8692423950C]
 
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M., Crettol S., Oneda B., Lahyani R., Rotger M., Choong E., Lubomirov R., Csajka C., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (2) pp. 84-93. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B0FCBF667C36]
 
Cytochrom-P450-Genotypisierung: ein Instrument zur Personalisierung der medikamentösenBehandlung in der Psychiatrie
Crettol Séverine, Eap Chin Bin, 2013. Pipette : Swiss Laboratory Medicine 6 pp. 10-11.
[URN][serval:BIB_0CD1E7557591]
 
Cytochromes P450: génotypage et /ou phénotypage pour l'individualisation du traitement médicamenteux
Crettol Séverine, Eap Chin B., 2013. Pipette 1 pp. 10-11.
[serval:BIB_99F58FB6F8C6]
 
Etude multicentrique: antidépresseurs, grossesse et allaitement.
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J.F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
[serval:BIB_05F36D52BCB4]
 
Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring.
Ansermot N., Brawand-Amey M., Kottelat A., Eap C.B., 2013. Journal of Chromatography. A, 1292 pp. 160-172. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BD61DC449C3A]
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D8852912657E]
Influence of CRTC1 Polymorphisms on Body Mass Index and Fat Mass in Psychiatric Patients and the General Adult Population.
Choong E., Quteineh L., Cardinaux J.R., Gholam-Rezaee M., Vandenberghe F., Dobrinas M., Bondolfi G., Etter M., Holzer L., Magistretti P. et al., 2013. JAMA Psychiatry, 70 (10) pp. 1011-1019. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1BC1C0DFA15B]
 
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M., Eap C.B., 2013. Clinical Pharmacokinetics, 52 (4) pp. 225-241. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9FA0DBC8CE5A]
Pharmacogenetic Study on Risperidone Long-Acting Injection: Influence of Cytochrome P450 2D6 and Pregnane X Receptor on Risperidone Exposure and Drug-Induced Side-Effects.
Choong E., Polari A., Kamdem R.H., Gervasoni N., Spisla C., Sirot E.J., Bickel G.G., Bondolfi G., Conus P., Eap C.B., 2013. Journal of Clinical Psychopharmacology, 33 (3) pp. 289-298. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_86C0833D4954]
 
Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers.
Dobrinas M., Cornuz J., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (5) pp. 286-292. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DE23A122EB32]
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF51D91AAB14]
 
Psychiatrie [Psychiatry].
Conus P., Despland J.N., Herrera F., Chanachev A., Eap C.B., Mall J.F., Ebbing K., von Gunten A., 2013. Revue Médicale Suisse, 9 (368) pp. 76-79. Peer-reviewed.
[Pmid][serval:BIB_DF73D375F2F9]
 
Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations.
Noetzli M., Guidi M., Ebbing K., Eyer S., Zumbach S., Giannakopoulos P., von Gunten A., Csajka C., Eap C.B., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 270-275. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A5DFF6BBD3DF]
 
Use of High Doses of Quetiapine in Bipolar Disorder Episodes are not Linked to High Activity of Cytochrome P4503A4 and/or Cytochrome P4502D6.
Khazaal Y., Preisig M., Chatton A., Kaufmann N., Bilancioni R., Eap C.B., 2013. Psychiatric Quarterly, 84 (3) pp. 329-335. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_155DB85F7C06]
2012
 
Adherence to antidepressant treatment: what the doctor thinks and what the patient says.
Loayza N., Crettol S., Riquier F., Eap C.B., 2012. Pharmacopsychiatry, 45 (5) pp. 204-207. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DCE377FB63ED]
 
Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension.
Guessous I., Dobrinas M., Kutalik Z., Pruijm M., Ehret G., Maillard M., Bergmann S., Beckmann J.S., Cusi D., Rizzi F. et al., 2012. Human Molecular Genetics, 21 (14) pp. 3283-3292. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1D2BE11940C7]
 
Clinical and pharmacogenetic study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population
Eap C, Vandenberghe F, Choong Eva, Ambresin A, Von Gunten A, Conus P, 2012. dans International Journal of Neuropsychopharmacology.
[WoS][serval:BIB_CCAD682D642D]
 
Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression
Jaquenoud Sirot E., Harenberg S., Vandel P., Mendonça Lima C.A., Perrenoud P., Kemmerling K., Zullino D.F., Hilleret H., Crettol S., Jonzier-Perey M. et al., 2012. pp. 45 - A10 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
[DOI][serval:BIB_6D36408A49CA]
 
Clinical Study on Psychotropic Drug Induced Weight Gain and Other Metabolic Complications in a Swiss Psychiatric Population
Choong Eva, Eap C, Von Gunten A, Conus P, 2012. dans Pharmacoepidemiology and Drug Safety.
[WoS][serval:BIB_5AABEA68256C]
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
[serval:BIB_4BDA40F2AC01]
 
Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking.
Dobrinas M., Cornuz J., Pedrido L., Eap C.B., 2012. Pharmacogenetics and Genomics, 22 (2) pp. 143-151. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FCB42CD14A0F]
 
Matched case-control study: therapeutic drug monitoring in pharmacovigilance
Jaquenoud Sirot E., Stephan P.L., Eap C.B., van der Velden J.W., Baumann P., 2012. pp. 45 - A11 dans Psychotropic Drugs: Risks and Risk Management : Xth Congress of the Interdisciplinary TDM Task Force of the AGNP together with the Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and the Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP), Pharmacopsychiatry. Peer-reviewed.
[DOI][WoS][serval:BIB_969E4BC34339]
 
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring/Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Eap Bin, 2012/01/01..
[DOI][WoS][serval:BIB_48054D8DFF76]
 
Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression.
Jaquenoud Sirot E.veline, Harenberg Sabine, Vandel Pierre, Lima Carlos .A., Perrenoud Patrick, Kemmerling Klaus, Zullino Daniele .F., Hilleret Henriette, Crettol Séverine, Jonzier-Perey Michèle et al., 2012. Journal of Clinical Psychopharmacology, 32 (5) pp. 622-629. Peer-reviewed.
[DOI][Pmid][serval:BIB_A42ABEFEA2B4]
 
Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population.
Choong E., Bondolfi G., Etter M., Jermann F., Aubry J.M., Bartolomei J., Gholam-Rezaee M., Eap C.B., 2012. Journal of Psychiatric Research, 46 (4) pp. 540-548. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B4C1EAC258AB]
 
Simultaneous determination of antidementia drugs in human plasma: Procedure transfer from HPLC-MS to UPLC-MS/MS.
Noetzli M., Ansermot N., Dobrinas M., Eap C.B., 2012. Journal of Pharmaceutical and Biomedical Analysis, 64-65 pp. 16-25. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_729D59AF62E3]
 
Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring.
Ansermot N., Brawand-Amey M., Eap C.B., 2012. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 885-886 pp. 117-130. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A240259C3DE5]
2011
 
La pharmacogénétique/pharmacogénomique en psychiatrie, perspectives théoriques et perspectives pour l'avenir
Chanachev Aleksandar, Conus Philippe, Eap Chin Bin, 2011/11. L'information psychiatrique, 87 (9) pp. 697-703.
[URN][serval:BIB_19F9C955F61D]
 
Syndrome métabolique et antipsychotiques atypiques : recommandations et prise en charge clinique
Solida Alessandra, Choong Eva, Lechaire Catherine, Eap Chin Bin, Conus Philippe, 2011/11. L'information psychiatrique, 87 (9) pp. 715-724.
[serval:BIB_801E95AC0389]
 
Syndrome métabolique et antipsychotiques atypiques: recommandations et prise en charge clinique
Solida Alexandra, Choong Eva, Eap Chin, 2011/11/01. L’Information psychiatrique, 87 (9) pp. 715-24.
[serval:BIB_38CA59D000DE]
 
14ème Journée de Recherche des Départements de Psychiatrie de Genève et de Lausanne
Choong E, Conus P, Eap C, Bondolfi G, Von Gunten A, Preisig M, 2011/06/01. dans Clinical and pharmacogenetic studies on response and side-effects under psychotropic drugs.
[serval:BIB_F75FCBF7ED3D]
Addition of aripiprazole to the clozapine may be useful in reducing anxiety in treatment-resistant schizophrenia.
Chanachev A., Ansermot N., Crettol Wavre S., Nowotka U., Stamatopoulou M.E., Conus P., Eap C.B., 2011. Case Reports In Psychiatry, 2011 p. 846489. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_70D83905314A]
 
Cytochrome P450 1A2 activity and inducibility: impact of smoking, smoking cessation and genetic polymorphisms
Dobrinas M., Cornuz J., Oneda B., Kohler S.M., Puhl M., Eap C.B., 2011. p. 473 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Therapeutic Drug Monitoring. Peer-reviewed.
[WoS][serval:BIB_651AFCC700D9]
 
Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study.
Nikisch Georg, Baumann Pierre, Oneda B., Kiessling B., Weisser H., Mathé A.A., Yoshitake T., Kehr J., Wiedemann G., Eap Chin B., 2011. Journal of Psychopharmacology, 25 (7) pp. 896-907. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B7D93AB98992]
 
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility.
Dobrinas M., Cornuz J., Oneda B., Kohler Serra M., Puhl M., Eap C.B., 2011. Clinical Pharmacology and Therapeutics, 90 (1) pp. 117-125. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7A4910B063E]
 
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring/Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Rentsch Katharina, Buhl Daniela, Eap Chin Bin, Fathi Marc, Thormann Wolfgang, Werner Dominique, 2011/01. LaboratoriumsMedizin, 35 (2) pp. 81-91. Peer-reviewed.
[URN][DOI][WoS][serval:BIB_18B42DC0B70C]
 
Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers.
Choong E, Bondolfi G, Eap C, Oneda B, Etter M, 2011/01/01. dans 31st Annual meeting of Swiss Society of Biological Psychiatry, January 2011, Lausanne, Switzerland..
[serval:BIB_3E507D03509E]
 
Psychiatrie [Psychiatry].
Guex P., Conus P., Pomini V., Kramer U., Bonsack C., Eap C., 2011. Revue Médicale Suisse, 7 (278) pp. 150-153. Peer-reviewed.
[Pmid][serval:BIB_EB85B71B9C22]
 
Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring.
Choong E., Rudaz S., Kottelat A., Haldemann S., Guillarme D., Veuthey J.L., Eap C.B., 2011. Journal of Chromatography. B, 879 (19) pp. 1544-1550. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5BEFDB40A967]
 
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation.
Dobrinas M., Choong E., Noetzli M., Cornuz J., Ansermot N., Eap C.B., 2011. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 879 (30) pp. 3574-3582. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_36445F679F00]
 
Simultaneous determination of antidementia drugs by HPLC-MS: validation data of the method and plasma level determinations in 300 patients
Noetzli M., Choong E., Ansermot N., Eap C.B., 2011. p. 501 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Therapeutic Drug Monitoring. Peer-reviewed.
[WoS][serval:BIB_76D89205506F]
 
Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring.
Noetzli M., Choong E., Ansermot N., Eap C.B., 2011. Therapeutic Drug Monitoring, 33 (2) pp. 227-238. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_982CF39955B2]
 
Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz.
Pelet A., Favrat B., Cavassini M., Eap C.B., Besson J., Monnat M., 2011. American Journal of Drug and Alcohol Abuse, 37 (4) pp. 264-268. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_674823703779]
 
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
Oneda B., Crettol S., Bochud M., Besson J., Croquette-Krokar M., Hämmig R., Monnat M., Preisig M., Eap C.B., 2011. Pharmacogenomics Journal, 11 (4) pp. 258-266. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_02BE3E233F45]
2010
 
Does Methadone Prolong QTc Intervals by Depleting Testosterone Levels?—Reply
Ansermot Nicolas, Albayrak Oezguer, Schlaepfer Juerg, Wavre Crettol Séverine, Croquette-Krokar Marina, Bourquin Michel, Deglon J.J., Faouzi M., Rey F., Scherbaum N. et al., 2010/08/09. Archives of Internal Medicine, 170 (15) p. 1407. Peer-reviewed.
[DOI][WoS][serval:BIB_C13BF53FCF4F]
 
Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval.
Ansermot N., Albayrak O., Schläpfer J., Crettol S., Croquette-Krokar M., Bourquin M., Déglon J.J., Faouzi M., Scherbaum N., Eap C.B., 2010/03/22. Archives of internal medicine, 170 (6) pp. 529-536. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2447D2DCD9A6]
 
Evidence-based medicine for pharmacogenetics
Rossier Michel F., Rebsamen Michaela, Crettol Severine, Eap Chin B., Rentsch Katharina, 2010. Pipette : Swiss Loboratory Medicine 4 pp. 13-15.
[serval:BIB_3432451F8CA0]
 
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., Rebsamen M.C., Rossier M.F., Hochstrasser D., Dayer P., Desmeules J.A., 2010. British Journal of Pharmacology, 160 (4) pp. 919-930. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B46F8324E084]
 
Lack of Association Between Genetic Polymorphisms of ARRB2 and Alcohol Dependence in a Caucasian Population.
Oneda B., Preisig M., Dobrinas M., Eap C.B., 2010. Alcohol and Alcoholism, 45 (6) pp. 590-591. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_54F1D1AB807E]
 
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring = Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werden
Rentsch K., Buhl D., Eap C.B., Fathi M., Jöchle W., Magnin J.L., Thormann W., Werner D., 2010. Laboratoriums-Medizin = Journal of Laboratory Medicine, 34 (3) pp. 129-139. Peer-reviewed.
[DOI][WoS][serval:BIB_9BD785D565D9]
 
Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers
Choong Eva, Eap C, 2010. pp. s214 dans European Neuropsychopharmacology.
[DOI][WoS][serval:BIB_71536CB58E69]
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
[URN][serval:BIB_34EABEDF4890]
 
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer C.F., Daali Y., Wagner M., Hopfgartner G., Eap C.B., Rebsamen M.C., Rossier M.F., Hochstrasser D., Dayer P., Desmeules J.A., 2010. British Journal of Pharmacology, 160 (4) pp. 907-918. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_455E2ECC59E1]
 
The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution.
Choong E., Dobrinas M., Carrupt P.A., Eap C.B., 2010. Expert Opinion On Drug Metabolism and Toxicology, 6 (8) pp. 953-965. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B9CC1CA46639]
2009
 
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B., Crettol S., Jaquenoud Sirot E., Bochud M., Ansermot N., Eap C.B., 2009/11. Pharmacogenetics and genomics, 19 (11) pp. 877-883. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_078310C1D51D]
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
[URN][serval:BIB_646DE6013BB6]
 
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E., Knezevic B., Morena G.P., Harenberg S., Oneda B., Crettol S., Ansermot N., Baumann P., Eap C.B., 2009/08. Journal of clinical psychopharmacology, 29 (4) pp. 319-326. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F54C2F3BEB3]
 
Aspects génétiques de la consommation de tabac et prise en charge clinique [Genetic aspects of smoking and impact on clinical care]
Dobrinas M., Cornuz J., Kohler Serra M., Puhl M., Eap C.B., 2009. Revue médicale suisse, 5 (210) pp. 1463-7. Peer-reviewed.
[Pmid][serval:BIB_0E76F96A505E]
Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study.
Hallinan R., Crettol S., Agho K., Attia J., Besson J., Croquette-Krokar M., Hämmig R., Déglon J.J., Byrne A., Ray J. et al., 2009. European Journal of Clinical Pharmacology, 65 (11) pp. 1113-1120.
[URN][DOI][WoS][Pmid][serval:BIB_879A09F2BE27]
 
CYP3A5 and ABCB1 genes and hypertension.
Bochud M., Bovet P., Burnier M., Eap C.B., 2009. Pharmacogenomics, 10 (3) pp. 477-487. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4D26D0016704]
 
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C. et al., 2009. Pharmacogenetics and Genomics, 19 (4) pp. 300-309. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_69748BF486BC]
Monographs on drugs which are frequently analyzed in therapeutic drug monitoring
Rentsch K., Eap C.B., Fathi M., Grignaschi N., Magnin J.L., Thormann W., Todesco L., Werner D., 2009. Journal of Laboratory and Clinical Medicine, 33 (2) pp. 99-120.
[URN][DOI][WoS][serval:BIB_B010C144075A]
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09C3908EC60D]
 
Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS.
Choong E., Rudaz S., Kottelat A., Guillarme D., Veuthey J.L., Eap C.B., 2009. Journal of Pharmaceutical and Biomedical Analysis, 50 (5) pp. 1000-1008. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A9702E4751B4]
 
Un regard sur la schizophrénie
Bertholet Léa, Do Kim Q., Schenk Françoise, Ansermot Nicolas, Eap Chin B., 2009. Actualités psychologiques 22 pp. 77-106.
[serval:BIB_3F4C90885A67]
 
Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples.
Ansermot N., Rudaz S., Brawand-Amey M., Fleury-Souverain S., Veuthey J.L., Eap C.B., 2009. Journal of Chromatography. B, 877 (23) pp. 2301-2307. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0D3A9161914E]
2008
 
Suivi du syndrome métabolique induit par les antipsychotiques atypiques: recommandations et perspectives pharmacogénétiques [Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives]
Choong E., Solida A., Lechaire C., Conus P., Eap C.B., 2008/09/17. Revue medicale suisse, 4 (171) pp. 1994-1996,1998-1999. Peer-reviewed.
[Pmid][serval:BIB_2191648F6C07]
 
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M., Eap C.B., Oneda B., Gervasoni N., Aubry J.M., Bondolfi G., Bertschy G., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 474-482. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_466AFA1A39D5]
 
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.
Fayet A., Béguin A., de Tejada B.M., Colombo S., Cavassini M., Gerber S., Eap C.B., Telenti A., Buclin T., Biollaz J. et al., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 511-522. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_14181C037D30]
 
ABCB1 and cytochromes P450 genotypes and phenotypes: influence on clozapine plasma concentrations
Jaquenoud Sirot Eveline, Knezevic B., Perla Morena Gina, Baumann Pierre, Eap Chin Bin, 2008. pp. e465 dans , Canadian Journal of Clinical Pharmacology = Journal canadien de pharmacologie clinique. Peer-reviewed.
[serval:BIB_8F425FA35787]
Association of ABCB1 genetic variants with renal function in Africans and in Caucasians.
Bochud M., Eap C.B., Maillard M., Johnson T., Vollenweider P., Bovet P., Elston R.C., Bergmann S., Beckmann J.S., Waterworth D.M. et al., 2008. BMC Medical Genomics, 1 (21) pp. 1-11. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D784077998C6]
 
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.
Crettol S., Besson J., Croquette-Krokar M., Hämmig R., Gothuey I., Monnat M., Déglon J.J., Preisig M., Eap C.B., 2008. Progress in Neuro-psychopharmacology and Biological Psychiatry, 32 (7) pp. 1722-1727. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5E88F9AD4B4A]
 
Brain dopamine response in human opioid addiction
Daglish Mark R.C., Williams Tim M., Wilson Sue J., Taylor Lindsay G., Eap Chin, Augsburger Marc, Giroud Christian, Brooks David J., Myles Judy S., Grasby Paul et al., 2008. British Journal of Psychiatry, 193 (1) pp. 65-72. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_12635496DEAC]
 
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.
Nikisch G., Eap C.B., Baumann P., 2008. Pharmacological research, 58 (5-6) pp. 344-347. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9AD9C8C6AC8A]
 
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S., Venetz J.P., Fontana M., Aubert J.D., Pascual M., Eap C.B., 2008. Therapeutic Drug Monitoring, 30 (6) pp. 689-699. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BC6922E390E7]
 
Dépendances : nouveautés en médecine 2007
Besson Jacques, Eap Chin-Bin, Khazaal Yasser, Montagrin Yves, Rihs-Middel Margret, Simon Olivier, Tissot Hervé, Tomei Alexander, Zumwald Coralie, Zullino Daniele Fabio, 2008. Revue médicale suisse, 4 (139) pp. 8-13. Peer-reviewed.
[serval:BIB_40A4061AF442]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University